These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 24478400)

  • 1. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.
    Lundberg P; Karow A; Nienhold R; Looser R; Hao-Shen H; Nissen I; Girsberger S; Lehmann T; Passweg J; Stern M; Beisel C; Kralovics R; Skoda RC
    Blood; 2014 Apr; 123(14):2220-8. PubMed ID: 24478400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms.
    Hinze A; Rinke J; Crodel CC; Möbius S; Schäfer V; Heidel FH; Hochhaus A; Ernst T
    Br J Haematol; 2023 Jul; 202(2):308-317. PubMed ID: 37139709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
    Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
    Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
    Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
    Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
    Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
    BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.
    Usseglio F; Beaufils N; Calleja A; Raynaud S; Gabert J
    J Mol Diagn; 2017 Jan; 19(1):92-98. PubMed ID: 27855276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
    Ha JS; Kim YK
    Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.
    Kurtovic-Kozaric A; Islamagic E; Komic H; Bilalovic N; Eminovic I; Burekovic A; Uzunovic A; Kurtovic S
    Bosn J Basic Med Sci; 2020 May; 20(2):236-247. PubMed ID: 31668145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
    Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
    Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
    Belcic Mikic T; Pajic T; Sever M
    Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
    Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
    Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic-pathologic characterization of myeloproliferative neoplasms.
    Kim Y; Park J; Jo I; Lee GD; Kim J; Kwon A; Choi H; Jang W; Chae H; Han K; Eom KS; Cho BS; Lee SE; Yang J; Shin SH; Kim H; Ko YH; Park H; Jin JY; Lee S; Jekarl DW; Yahng SA; Kim M
    Exp Mol Med; 2016 Jul; 48(7):e247. PubMed ID: 27444979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
    Martin S; Wright CM; Scott LM
    Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
    Smaili W; Doubaj Y; Laarabi FZ; Lyahyai J; Kerbout M; Mikdame M; Sefiani A
    Curr Res Transl Med; 2017; 65(1):15-19. PubMed ID: 28340692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations.
    Yang HS
    Cancer Biomark; 2016; 17(4):383-389. PubMed ID: 27662324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms.
    Chang YC; Lin HC; Chiang YH; Chen CG; Huang L; Wang WT; Cheng CC; Lin J; Chang YF; Chang MC; Hsieh RK; Chen SJ; Lim KH; Kuo YY
    Med Oncol; 2017 May; 34(5):83. PubMed ID: 28389907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation.
    Haunstrup LM; Ebbesen LH; Hansen M; Severinsen MT; Aggerholm A
    Exp Hematol; 2018 Dec; 68():62-65. PubMed ID: 30292681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.
    Wang J; Hao J; He N; Ji C; Ma D
    Turk J Haematol; 2016 Sep; 33(3):180-6. PubMed ID: 26377485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.